Back to Report Store Home

Frontier Pharma: Parkinson’s Disease - Identifying and Commercializing First-in-Class Innovation

  • Published: Jan-2016
  • Report Code: GBIHC398MR
  • Report Format: pdf


Parkinson’s Disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease, affecting around 7.4 million people worldwide. It is caused by the progressive loss of dopamine-producing neurons in the substantia nigra within the basal ganglia. The main motor symptoms are tremors, bradykinesia and rigidity, although symptoms vary between individuals. As the disease progresses to more advanced stages, increasing symptoms and complications develop, which can cause severe disability in patients.

The current market offers a number of anti-PD treatment options which provide symptomatic relief. Levodopa is currently the gold standard therapy, with other drug classes including dopamine agonists and Monoamine Oxidase B (MAO-B) inhibitors also used to treat early and advanced cases. With no current treatment showing effectiveness in delaying the course of the disease, PD remains incurable. The high unmet need for a disease-modifying therapy is reflected in the pipeline, where a high proportion of early-stage first-in-class programs target the potential pathogenic mechanisms underlying neurodegeneration.


  • PD is a crowded market with many neuromodulatory drug classes available. However, a disease-modifying therapy with neuroprotective effects is yet to be developed.

  • What are the primary mechanisms that are thought to contribute to neuronal death?

  • What are the major barriers facing the development of investigational neuroprotective candidates?

  • Analysis reveals a high level of innovation and diversity in the pipeline, with 121 first-in-class programs acting on 57 unique molecular targets.

  • Neuromodulatory targets remain the dominant target family, particularly in the late-stage pipeline.

  • What are the first-in-class families with a significant presence?

  • How well do they align with the underlying pathways governing neuronal death in PD?

  • Some of the first-in-class targets have a potentially stronger chance of being translated into novel treatments for PD.

  • What is the scientific rationale behind these targets? How do they perform in Preclinical studies?

  • What are the commonly used disease models and the parameters measuring neuroprotective effects in PD animal studies?

  • Deals involving first-in-class PD products are more likely to be made in earlier stages of development than non-first-in-class deals.

  • What is the dominant molecular target in the PD deals landscape?

  • What are the promising first-in-class products still available for future licensing?

Reasons To Buy

  • This report will allow you to:

  • Understand the current clinical and commercial landscape by considering the proposed pathogenic processes underlying PD neurodegeneration, diagnosis, prognosis, and the available treatment options and their usage in early and advanced PD.

  • Visualize the composition of the PD market to highlight the current unmet needs in order to gain a competitive understanding of the key opportunities.

  • Analyze the PD pipeline and stratify by stage of development, molecule type, and molecular target – the diversity of molecular targets in the pipeline is extremely encouraging due to the multifaceted nature of PD.

  • Assess the therapeutic potential of first-in-class targets using a proprietary matrix that assesses and ranks first-in-class products according to clinical potential.

  • Target the most promising and innovative PD products for early-stage investment by analyzing trends in licensing and co-development deals and accessing a curated list of first-in-class therapies potentially open to deal-making opportunities.

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments